• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Why Are Innovative Drugs Failing in Phase III?

作者信息

Marder Stephen R, Laughren Thomas, Romano Steven J

机构信息

From the Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles; the VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; Laughren Psychopharmacology Consulting, Rockville, Md.; and Mallinckrodt Pharmaceuticals, St. Louis.

出版信息

Am J Psychiatry. 2017 Sep 1;174(9):829-831. doi: 10.1176/appi.ajp.2017.17040426.

DOI:10.1176/appi.ajp.2017.17040426
PMID:28859511
Abstract
摘要

相似文献

1
Why Are Innovative Drugs Failing in Phase III?创新药物为何在三期试验中失败？
Am J Psychiatry. 2017 Sep 1;174(9):829-831. doi: 10.1176/appi.ajp.2017.17040426.
2
Genomics drugs in clinical trials.处于临床试验阶段的基因组学药物。
Nat Rev Drug Discov. 2010 Dec;9(12):988. doi: 10.1038/nrd1552-c1.
3
Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development.银屑病系统性药物III期试验的纳入和排除标准：药物研发的外部有效性
Br J Dermatol. 2016 Sep;175(3):636-8. doi: 10.1111/bjd.14622. Epub 2016 Jul 5.
4
Accelerated drug development through combined phase 2/3 clinical trial design.通过2/3期联合临床试验设计加速药物研发。
Arch Ophthalmol. 2004 Jul;122(7):1043-4. doi: 10.1001/archopht.122.7.1043.
5
A need for speed: Signals in drug development.对速度的需求：药物研发中的信号
Nat Med. 2012 Dec;18(12):1730-1. doi: 10.1038/nm1212-1730.
6
Eyes on new product development.关注新产品开发。
J Ocul Pharmacol Ther. 2013 Oct;29(8):701. doi: 10.1089/jop.2013.1510.
7
Eyes on New Product Development.
J Ocul Pharmacol Ther. 2016 Jul-Aug;32(6):341-2. doi: 10.1089/jop.2016.29015.gdn. Epub 2016 Jun 22.
8
Marc Kirschner. Interview by Asher Mullard.马克·基尔希纳。阿舍·穆拉德采访。
Nat Rev Drug Discov. 2011 Dec 1;10(12):894. doi: 10.1038/nrd3613.
9
Are medication-free periods necessary for phase 3 trials of new antipsychotic drugs?
Arch Gen Psychiatry. 1998 Mar;55(3):280-1; 283. doi: 10.1001/archpsyc.55.3.280.
10
Trends in risks associated with new drug development: success rates for investigational drugs.新药研发相关风险趋势：研究药物的成功率。
Clin Pharmacol Ther. 2010 Mar;87(3):272-7. doi: 10.1038/clpt.2009.295. Epub 2010 Feb 3.

引用本文的文献

1
The neuroreceptors and transporters underlying spontaneous brain activity.自发性脑活动背后的神经受体和转运体。
Commun Biol. 2025 Jul 30;8(1):1130. doi: 10.1038/s42003-025-08492-z.
2
Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges.治疗抵抗性抑郁症的新兴药物：机制与挑战视角的综述
Brain Sci. 2025 Feb 6;15(2):161. doi: 10.3390/brainsci15020161.
3
Drug targeting in psychiatric disorders - how to overcome the loss in translation?精神疾病的药物靶向治疗——如何克服转化中的损失？
Nat Rev Drug Discov. 2024 Mar;23(3):218-231. doi: 10.1038/s41573-023-00847-7. Epub 2023 Dec 19.
4
Experimental Medicine Approaches in Early-Phase CNS Drug Development.中枢神经系统药物早期研发中的实验医学方法
Adv Neurobiol. 2023;30:417-455. doi: 10.1007/978-3-031-21054-9_17.
5
An Update on Treatment of Cognitive Impairment Associated with Schizophrenia.精神分裂症相关认知障碍治疗的最新进展
Curr Top Behav Neurosci. 2023;63:407-436. doi: 10.1007/7854_2022_382.
6
The Relative Effects of Prazosin on Individual PTSD Symptoms: Evidence for Pathophysiologically-Related Clustering.哌唑嗪对个体创伤后应激障碍症状的相对影响：病理生理相关聚类的证据。
Chronic Stress (Thousand Oaks). 2021 Feb 9;5:2470547020979780. doi: 10.1177/2470547020979780. eCollection 2021 Jan-Dec.
7
John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials.约翰·D·洛泽奖讲座：规模很重要，但并非一切：慢性疼痛临床试验中适度治疗效果的挑战
Pain. 2020 Sep;161 Suppl 1(1):S3-S13. doi: 10.1097/j.pain.0000000000001849.
8
α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future.α7 烟碱型乙酰胆碱受体在精神分裂症中的治疗靶点：动物和临床研究的最新进展及未来策略。
Neuropharmacology. 2020 Jun 15;170:108053. doi: 10.1016/j.neuropharm.2020.108053. Epub 2020 Mar 15.
9
Number Of Clinical Trial Study Sites Impacts Observed Treatment Effect Size: An Analysis Of Randomized Controlled Trials Of Opioids For Chronic Pain.临床试验研究地点的数量影响观察到的治疗效应大小：阿片类药物治疗慢性疼痛的随机对照试验分析
J Pain Res. 2019 Nov 20;12:3161-3165. doi: 10.2147/JPR.S201751. eCollection 2019.
10
An Innovative Disease-Drug-Trial Framework to Guide Binge Eating Disorder Drug Development: A Case Study for Topiramate.一种创新的疾病-药物试验框架，用于指导暴食障碍药物的开发：以托吡酯为例的案例研究。
Clin Transl Sci. 2020 Jan;13(1):88-97. doi: 10.1111/cts.12682. Epub 2019 Sep 9.